The author bought Cardiff Oncology (CRDF) after Gary Pace's insider purchase of over $1M, viewing the insider's cost basis as an anchor since the stock has not yet reached it. The stated catalyst is positive news from the court case with NMS; the author argues even a preliminary injunction, not just a full settlement, would send shares higher. The main risk implied is that the court case outcome is uncertain and the thesis depends on a favorable legal development.